Our Story
Our beginning...
In preclinical research, led by Søren P. Sheikh, the promising potential of adipose-derived stem cells has been demonstrated in a rat model for erectile dysfunction.
Therefore, Søren P. Sheikh embarked on a mission to bring stem cell treatment to patients with erectile dysfunction. A disease with a high prevalence and an unmet therapeutic need.
In 2016, the Danish Medicines Agency approved a phase I clinical trial using autologous adipose-derived stem cells to treat erectile dysfunction after prostate cancer surgery.
The men included in the phase I clinical trial had no erectile function and did not respond to drugs like Viagra. The results were promising, with 72% of the men regaining erectile function and the ability to engage in sexual intercourse 6 months after the treatment.
The autologous adipose derived stem cells used in the clinical study required liposuction and an on-site isolation of autologous adipose derived stem cells. This limits the availability of the treatment. Thus, Søren P. Sheikh decided to develop standardized methods to isolate and culture the stem cells while maintaining or even enhancing the biological effects.
Søren founded Blue Cell Therapeutics and gathered a team around him to make an ‘off-the-shelf’ allogenic stem cell therapy product as curative treatment for erectile dysfunction now known as the Blue Cell Therapy.
Since then, our team has evolved to establish a highly profiled management team and a skilled and dedicated group of scientist.
